Dan Hicklin, Werewolf CEO

Neu­ro play­er Jazz Phar­ma­ceu­ti­cals dives in­to im­muno-on­col­o­gy, ink­ing cy­tokine pact with Were­wolf

Jazz Phar­ma­ceu­ti­cals and Were­wolf Ther­a­peu­tics are team­ing up on a new im­muno-on­col­o­gy pact, one that could see Were­wolf in line for more than a $1 bil­lion pay­day.

The com­pa­nies an­nounced they are col­lab­o­rat­ing on WTX-613, a Were­wolf-dis­cov­ered in­ter­fer­on al­pha com­pound cur­rent­ly in the pre­clin­i­cal phase. Jazz is pony­ing up $15 mil­lion in up­front cash and is promis­ing up to $1.26 bil­lion in mile­stones, should they all be reached. Were­wolf can al­so re­ceive tiered mid-sin­gle-dig­it per­cent­age roy­al­ties on net sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.